Nanotechnology may improve gene therapy for blindness

PORTLAND, Oregon -- Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness.

A collaborative team of researchers with Oregon Health & Science University and Oregon State University have developed an approach that uses lipid nanoparticles — tiny, lab-made balls of fat — to deliver strands of messenger ribonucleic acid, or mRNA, inside the eye. To treat blindness, the mRNA will be designed to create proteins that edit vision-harming gene mutations.

In a study published today in Science Advances, the team demonstrates how its lipid nanoparticle delivery system targets light-sensitive cells in the eye, called photoreceptors, in both mice and nonhuman primates. The system’s nanoparticles are coated with a peptide that the researchers identified as being attracted to photoreceptors.

“Our peptide is like a zip code, and the lipid nanoparticles are similar to an envelope that sends gene therapy in the mail,” explained the study’s corresponding author, Gaurav Sahay, Ph.D., an associate professor in the OSU College of Pharmacy who also has a joint research appointment at the OHSU Casey Eye Institute. “The peptide ensures mRNA is precisely delivered to photoreceptors — cells that we haven’t been able to target with lipid nanoparticles until now.”

“More than 250 genetic mutations have been linked to inherited retinal diseases, but only one has an approved gene therapy,” added study co-author Renee Ryals, Ph.D., an assistant professor of ophthalmology in the OHSU School of Medicine and a scientist at the OHSU Casey Eye Institute. “Improving the technologies used for gene therapy can provide more treatment options to prevent blindness. Our study’s findings show that lipid nanoparticles could help us do just that.”

In 2017, the Food and Drug Administration approved the first gene therapy to treat an inherited form of blindness. Many patients have experienced improved vision and have been spared blindness after receiving the therapy, which is sold under the brand name Luxturna. It uses a modified version of the adeno-associated virus, or AAV, to deliver gene-revising molecules.

Today’s gene therapies largely rely on AAV, but it has some limitations. The virus is relatively small and can’t physically contain gene-editing machinery for some complex mutations. And AAV-based gene therapy can only deliver DNA, which results in the continual creation of gene-editing molecules that may lead to unintended genetic edits.

Lipid nanoparticles are a promising alternative because they don’t have size constraints like AAV. Additionally, lipid nanoparticles can deliver mRNA, which only keeps gene-editing machinery active for a short period of time, so could prevent off-target edits. The potential of lipid nanoparticles was further proved by the success of mRNA-based COVID-19 vaccines, which also use lipid nanoparticles to deliver mRNA. They also were the first vaccines to be authorized for COVID-19 in the United States, thanks to the speed and volume at which they can be manufactured.

In this study, Sahay, Ryals and colleagues demonstrated that a peptide-covered lipid nanoparticle shell can be directed toward photoreceptor cells in the retina, tissue in the back of the eye that enables sight. As a first proof of concept, mRNA with instructions to make green fluorescent protein was placed inside nanoparticles.

After injecting this nanoparticle-based gene therapy model into the eyes of mice and nonhuman primates, the research team used a variety of imaging techniques to examine the treated eyes. The animals’ retinal tissue glowed green, illustrating that the lipid nanoparticle shell reached photoreceptors and that the mRNA it delivered successfully entered the retina and created green fluorescent protein. This research marks the first time that lipid nanoparticles are known to have targeted photoreceptors in a nonhuman primate.

The scientists are currently working on follow-up research to quantify how much of the green fluorescent protein is expressed in animal retinal models. They’re also working to develop a therapy with mRNA that carries the code for gene-editing molecules. 

Sahay and Ryals will continue developing their nanoparticle gene therapy delivery system with the support of a new, $3.1-million grant from the National Eye Institute of the National Institutes of Health. 

This research was supported by the National Eye Institute (grants 1R21EY031066, 1R01EY033423-01A1 and P30 EY010572), Oregon National Primate Research Center (pilot grant), the PhRMA Predoctoral Drug Delivery Fellowship, National Institutes of Health’s Office of Research Infrastructure Programs (grants P51 OD011092 and S10RR024585) and Research to Prevent Blindness.

Marco Herrera-Barrera, Renee C. Ryals and Gaurav Sahay are listed as co-inventors in a patent application based of this work.

In our interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regard to this research, Sahay has a significant financial interest in Enterx Biosciences, a company that may have a commercial interest in the results of this research and technology. Review details of OHSU's conflict of interest program to find out more about how we manage these business relationships.

All research involving animal subjects at OHSU must be reviewed and approved by the university’s Institutional Animal Care and Use Committee (IACUC). The IACUC’s priority is to ensure the health and safety of animal research subjects. The IACUC also reviews procedures to ensure the health and safety of the people who work with the animals. The IACUC conducts a rigorous review of all animal research proposals to ensure they justify the use of live animals and species selected; outline steps to minimize pain and distress; document appropriate training of all staff involved; and, establish, through a detailed review of published sources, the proposed study does not unnecessarily duplicate previous research. No live animal work may be conducted at OHSU without IACUC approval.

REFERENCE: Marco Herrera-Barrera, Renee C. Ryals, Milan Gautam, Antony Jozic, Madeleine Landry, Tetiana Korzun, Mohit Gupta, Chris Acosta, Jonathan Stoddard, Rene Reynaga, Wayne Tschetter, Nick Jacomino, Oleh Taratula, Conroy Sun, Andreas K. Lauer, Martha Neuringer, Gaurav Sahay, “Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates,” Science Advances, Jan. 11, 2023, DOI: 10.1126/sciadv.add4623.

Links:

• Oregon State University researcher take key step toward new treatment for hereditary blindness (OSU, 1/11/23)
• Gene Therapy Basics (American Society of Gene & Cell Therapy)
• Without these lipid shells, there would be no mRNA vaccines for COVID-19 (Chemical & Engineering News, March 6, 2021)
• OHSU Casey Eye Institute website
• Sahay Lab website

Related OHSU News stories:

• Nanotechnology may better identify, treat ectopic pregnancy (Nov. 21, 2022)
• High hopes for 4-year-old’s vision after gene therapy (Oct. 16, 2018)
• OHSU to provide new, FDA-approved gene therapy for a form of blindness (Dec. 26, 2017)